Classical t(11;14)(q13;q32) involving IGH-CCND1 is typically associated with aggressive CD5-positive mantle cell lymphoma (MCL). Recently, we identified the IGK variant of this translocation, t(2;11)(p11;q13), in three patients with a leukemic smallcell B-non-Hodgkin lymphoma. In all cases, rearrangements of the IGK and CCND1 genes were demonstrated by fluorescence in situ hybridization. Moreover, we mapped the 11q13 breakpoint of this variant translocation in the 3 0 region of CCND1 which contrasts with the 5 0 breakpoints in a standard t(11;14)(q13;q32). Expression of cyclin D1 was shown in two cases analyzed either at diagnosis or during disease progression. All three patients were asymptomatic at presentation and no initial therapy was required. One patient died of a progressive disease 58 months from diagnosis, and two patients showed stable disease after 12 months of follow-up. In two analyzed cases, mutated IGVH genes were identified. Our findings indicate that variant t(2;11)(p11;q13) does not typify a classical MCL but possibly a more indolent leukemic lymphoma originating from an antigen experienced (mutated) B cell.
Introduction
Translocation t(11;14)(q13;q32) hallmarks mantle cell lymphoma (MCL), an aggressive disease with well-defined histology and IGM þ /IGD þ , CD5 þ , CD19 þ , CD20 þ and CD79b þ immunophenotype. 1 Molecularly, t(11;14)(q13;q32) leads to overexpression of cyclin D1 (CCND1), a cell cycle regulator that is usually not expressed at high levels in normal B cells, 2 by its translocation in the vicinity of IGH regulatory sequences. 3 The same cytogenetic aberration, however, has also been observed in 15-20% of multiple myeloma (mm), B-prolymphocytic leukemia and splenic marginal zone lymphoma cases. [4] [5] [6] [7] [8] [9] [10] [11] While the IGH breakpoints in MCL-associated t (11;14) are usually located in the JH region, the IGH breakpoints in MM typically occur in the switch regions, indicating the involvement of the respective VDJ recombination and immunoglobulin switch class recombination mechanisms in their development. Interestingly, prognostic significance of t (11;14) differs: in MCL, it heralds a poor clinical outcome but in MM this translocation predicts a long survival. 12 In contrast to other lymphoma-associated oncogenes, like CMYC, BCL2 and BCL6, activated by their juxtaposition with either immunoglobulin heavy chain genes (IGH-14q32) or light chain genes (IGK-2p11 and IGL-22q11), the CCND1 locus (called also BCL1) is preferentially rearranged by its translocation to IGH. So far, only one case of IGL variant translocation, t(11;22)(q13;q11), found in MCL, has been published. 13, 14 We report here three cases of small-cell B-non-Hodgkin lymphoma (NHL) with the IGK variant translocation t(2;11)(p11;q13) and expression of cyclin D1 that did not display the typical features of MCL.
Study design

Patients
Cases were collected from files of the Center for Human Genetics, Katholieke Universiteit Leuven.
Flow cytometry
Flow cytometry was performed on peripheral blood using directly labeled monoclonal antibodies (FITC or PE) and a standard lyse and wash technique.
Immunohistochemistry (IHC)
IHC was performed on deparaffinized spleen sections using cyclin D1 antibody (Klinipath Belgium, Geel, Belgium) and a standard streptavidin-biotin-peroxidase technique.
Cytogenetics and fluorescence in situ hybridization (FISH)
R-banding analysis and FISH were performed according to standard procedures. Applied probes included LSI IGH SpectrumGreen/CCND1 Spectrum Orange, LSI p16 Spectrum Orange/CEP9 SpectrumGreen, LSI p53 Spectrum Orange (Vysis, Downers Grove, IL, USA), 11q13 cosmids (6.7, 6.22, 3.62 and 3.91), 15, 16 IGK BAC clones (RP11-316G9 -Spectrum Orange, RP11-1021F11 and P11-525L16 G -SpectrumGreen) 17 and 8p23.1 BAC clones (RP11-211C9 and RP11-375N15) (www.ensembl.org). Noncommercial probes were directly labeled using SpectrumOrange-and SpectrumGreen-dUTP (Vysis, Downers Grove, IL, USA). 17 One to five abnormal metaphases were evaluated in each experiment. Metaphase FISH findings have been confirmed on the interphase cell level.
Reverse transcriptase-polymerase chain reaction (RT-PCR)
The cDNA was made by reverse transcription of 2 mg total RNA. The template (2 ml) was amplified by AmpliTaq Gold polymerase with the forward primer 5 0 -CTGGCCATGAACTACCTGGA-3 0 (cyclin D1 sequence: accession no. M 64349) and the reverse primer 5 0 -GTCACACTTGATCACTCTGG-3 0 at 651C for 35 cycles which yielded a cyclin D1 product of 483 bp. In total, 15 ml of the PCR product was submitted to polyacrylamide gel electrophoresis, stained with ethidium bromide and photographed.
VH mutation analysis
IGVH gene mutational studies of DNA followed protocols described elsewhere. 18 The sequencing procedure was performed using an ABI PRISM 3100 variant (Applera, Foster City, CA, USA), according to the manufacturer's procedure. Mutations were identified by comparison of the sequence (adjusted with SeqMan II) with the germline IGH sequence provided by IMGT/V-Quest (http://imgt.cines.fr). The cutoff of 98% homology to the germline sequence was chosen to discriminate mutated (less than 98% homology) cases.
Results and discussion
We collected three cases with B-cell lymphoproliferative disorders documented by the t(2;11)(p11;q13) that was identified at the time of diagnosis in the involved bone marrow (cases 1-2) and the peripheral blood cells (case 3). There were two female patients and one male patient ranging in age from 48 to 71 years (average 61). The relevant clinical and immunophenotypic findings are shown in Table 1 . Results of cytogenetic and FISH studies are summarized in Table 2 . Karyotypes of present cases were relatively simple and the t(2;11) appeared as a sole aberration in subclones found in two cases. Involvement of the CCND1 and IGK loci in the t(2;11)(p11;q13) was initially studied by metaphase FISH with the dual color LSI IGH/CCND1 and IGK assays. 17 Briefly, the first experiment showed a normal localization of the IGH probe and presence of three CCND1 signals on the normal chromosome 11 and both derivatives of t(2;11) in all three analyzed cases (examples in Figure 1a ). The second experiment showed separation of the IGK hybridization signals on the der(2) and der (11) (Figure 1b) . The 11q13 breakpoint of case 2 was additionally investigated using a set of 11q13 cosmid clones from the CCND1 region mapped as follows: cent-cos6.7-MTC (major translocation cluster) -cos6.22/CCND1-cos3.62-cos3.91-tel. 15, 16 All five evaluated cells showed a split signal of cos6.22 that hybridized to the der(11) (strong signal) and the der(2) (diminished signal; see Figure 1c ). Among the remaining clones, cos6.7 hybridized to the der(11) and cos3.62 and cos3.91 hybridized to the der(2), as expected (example in Figure 1d ). Two cosmids, 6.22 and 3.62, further applied on metaphases from cases 1 and 3 showed the same hybridization pattern as in case 2 ( Table 2 ). Considering that cos6.22 covers the entire locus of CCND1 orientated towards the cent-5 0 CCND1 3 0 -tel, our FISH findings indicate that the breakpoint occurred in the 3 0 region of CCND1, as in the previously reported case with t(11;22)(q13;q11). 13, 14 These breakpoints in variant CCND1 translocations contrast with the 11q13 breakpoints in a standard t(11;14)(q13;q32) that spread in the centromeric region of CCND1. 16, 20 Thus, as for CMYC 21 and BCL2 22 variants, there is a variation in the breakpoints around CCND1. Owing to a shortage of material, we could demonstrate expression of cyclin D1 in only one diagnostic sample from case 3 analyzed by RT-PCR ( Figure 2 ) and in one progressive spleen biopsy from case 1 analyzed by IHC (Figure 1e ). Although Variant CCND1 rearrangement in leukemic B-cell lymphoma I Wlodarska et al limited, our data indicate that the variant IGK rearrangements with breakpoints in the 3 0 region of CCND1 deregulate expression of cyclin D1 in an analogous way as the standard rearrangements with breakpoints clustered upstream the gene.
Considering that MCL cases show recurrent deletions of the 8p, 9p21 and 17p13 chromosomal regions, 23 we additionally performed FISH analysis of these regions in the present cases. Indeed, loss of one 8p23 signal was found in case 1 with r(8) and loss of one 17p13/p53 signal was detected in a subclone with i(17)(q10) in case 3. Deletions of 9p21/p16 associated with shorter survival of MCL 24 were not detected in any of the present cases.
IGVH mutation analysis performed in cases 2 and 3 showed a clonal B-cell population with a functional VDJ gene in both cases. Those segments displayed, respectively, 19 and 10 missense mutations from the germ line, giving a mutation rate of 3.5% in case 2 and 6.5% in case 3. In both cases, the VH1-3 gene was mutated (Table 3) .
Clinically, all three patients were asymptomatic at presentation but showed lymphocytosis ranging from 10.1 to 17.3n10e9/ l during a routine check-up. As physical examination was normal, no initial therapy was started. Case 1 with an initial lymphocytosis of 17.3n10e9/l in January 1996 showed a stable disease for 1 year, and then the patient was lost to follow-up. After 48 months, the patient returned with a lymphocytosis of 90.4n10e9/l and massive splenomegaly. At that time a cytoreductive therapy with chlorambucil for hyperlymphocytosis was initiated and splenectomy was performed 4 months later. At diagnosis, the morphology of the circulating neoplastic cells in case 1 was heterogeneous (Figure 1f-i) and cells showed the CD5À, CD19 þ , CD22 þ , CD38 w þ , FMC7 þ and sIgA/ lambda þ immunophenotype. A diagnosis of leukemic smallcell B-NHL was made. After 4 years, biopsies taken from the splenectomy specimen showed a massive involvement of the white pulp of the spleen by small irregular lymphoid cells. Small nodules composed of a similar cell population were found within the red pulp. Both populations expressed pan B-cell markers, CD5 and cyclin D1, which are features of MCL (Figure 1e ). The IGK and CCND1 rearrangement in this sample was demonstrated by interphase FISH (Figure 1a/b) . Neoplastic bone marrow cells of case 2 presented the morphology of B-CLL cells, but immunophenotyping showed a CD5À, CD19 þ , CD22 þ , FMC7 þ , CD38À and sIgG/kappa þ profile. A diagnosis of small-cell B-NHL was made. Circulating leukemic cells in case 3 were pleomorphic and some of them displayed B-CLL cell features. The immunophenotype was CD5À, CD19 þ , CD79b þ , CD38À and sIgG/kappa þ . A bone marrow biopsy, taken at the same time, showed involvement of a small-cell B-NHL, not otherwise subtyped.
As shown above, clinicopathological features of patients with the variant t(2;11)(p11;q32) markedly contrast with characteristics of patients with a standard MCL-associated t(11;14)(q13;q32). While the latter aberration hallmarks a clinically aggressive IGVH unmutated MCL, the IGK-variant translocation was found in rather indolent small B-cell malignancies that did not fulfill criteria for either MCL or CLL (Matutes score 0À1/5). Moreover, both analyzed cases showed mutated IGVH genes, indicative of a more mature B-cell origin but without features of plasma cells. Interestingly, similar features have been recently described in a subset of t(11;14) lymphoma with mantle cell characteristics but with an indolent clinical course and long survival. 25 Like ours, these cases Spleen biopsy from this case was not subjected to cytogenetic analysis.
Variant CCND1 rearrangement in leukemic B-cell lymphoma I Wlodarska et al showed frequently a lymphocytosis without nodal involvement and mutated IGVH genes. They usually pose diagnostic problems and are considered as MCL mainly because of the presence of t (11;14) . A tendency of longer survival of mutated MCL cases has also been noted by other groups. [26] [27] [28] [29] Association of the mutated IGVH genes and stable disease, and unmutated IGVH genes and progressive disease has been previously identified in CLL. 30, 31 In summary, our study demonstrates that the variant t(2;11)(p11;q13)/IGK-CCND1 aberration associated with rear- Figure 1 Morphologic, immunophenotypic and molecular cytogenetic findings. Examples of FISH with the dual color LSI IGH/CCND1 (a), break apart IGK (b), cos6.22 (green)/cos3.91 (red) (c), and cos6.7 (green )/cos3.62 (red) (d) assays performed in cases 1 (a, b) and 2 (c, d). In insets, interphase cells from the spleen biopsy from case 1 showing the same FISH pattern as a diagnostic sample. Arrows and arrowheads indicate the der(2) and the der(11), respectively. Note the split of CCND1 (red) (a) and cos6.22/CCND1 (c) signals, and separation of the IGK (b) and cos6.7/ cos3.62 (d) signals on the der(2) and der(11) chromosomes. Examples of cyclin D1 (e) and May-Grü nwald-Giemsa (f-i) staining performed on spleen biopsy and peripheral blood cells from case 1 showing a wide morphological spectrum of neoplastic cells with lymphoplasmocytic (f,g), villous (h), and MCL-like (I) features. Variant CCND1 rearrangement in leukemic B-cell lymphoma I Wlodarska et al rangement in the 3 0 region of CCND1 and expression of cyclin D1 is a recurrent molecular feature of leukemic small-cell B-NHL showing mutated IGVH. The clinical course appears to be more indolent than in MCL; however, further studies are required to determine whether the variant (2;11) translocation can be considered as a good prognostic factor.
Finally, whether this lymphoma represents an indolent variant of MCL or corresponds to splenic marginal zone cell lymphoma/ splenic lymphoma with villous lymphocytes associated with t(11;14), as previously described by Catovsky and co-workers, [6] [7] [8] is open for discussion.
